Table 1.
Patients’ characteristics
| Lung cancer (n=23) |
Colorectal cancer (n=8) | Prostate cancer (n=2) | Pancreatic cancer (n=1) | Lymphoma (n=1) | Noncancer (n=40) | P-value | |
|---|---|---|---|---|---|---|---|
| Gender | 1.0000 | ||||||
| Male | 17 | 5 | 2 | 0 | 1 | 29 | |
| Female | 6 | 3 | 0 | 1 | 0 | 11 | |
| Age, years | 0.0514 | ||||||
| Median | 85 | 87.5 | 86.5 | 83 | 80 | 89.5 | |
| Range | 80–98 | 80–98 | 83–90 | / | / | 80–110 | |
| Biomarker expression level, median (IQR) | |||||||
| FR+CTC, CTC U/3 mL | 14.1 (11.8–18.4) |
18.8 (9.7–22.8) |
12.1 (4.6–19.6) |
8.8 | 16.1 | 9.2 (7.1–12.5) |
0.0002 |
| CA125, U/mL | 68.9 (27.7–167.2) |
14.7 (8.2–67.9) |
67.1 (8.2–126.0) |
135.7 | 28.2 | 16.8 (8.3–33.2) |
0.0028 |
| CA199, U/mL | 18.8 (8.7–30.6) |
25.4 (14.6–87.7) |
109.2 (12.4–206.0) |
239.7 | 14.2 | 15.4 (9.8–23.8) |
0.1284 |
| CEA, ng/mL | 5.2 (2.6–13.3) |
4.2 (3.5–7.6) |
12.7 (2.2–23.4) |
6.3 | 2.5 | 4.2 (2.5–5.5) |
0.1257 |
| CYFRA21-1, ng/mL | 5.6 (5.0–25.4) |
3.2 (2.2–5.8) |
5.7 (1.4–10.0) |
3.1 | ND | 3.3 (2.5–5.5) |
0.0102 |
| CA724, U/mL | 2.9 (0.9–8.8) |
2.6 (1.0–8.5) |
1.5 | 1.1 | ND | 1.9 (0.9–3.5) |
0.2024 |
| NSE, ng/mL | 15.0 (11.0–26.0) |
12.7 (10.1–14.0) |
15.4 (15.0–15.8) |
16.9 | ND | 10.2 (8.4–12.2) |
<0.0001 |
Notes: CYFRA21-1, CA724, and NSE tests had not performed for the lymphoma patient. P-value: comparison between the cancer group and the noncancer group.
Abbreviation: IQR, interquartile range; FR+CTC, folate receptor-positive circulating tumor cell; CTC U, circulating tumor cell unit; CA, carbohydrate antigen; CEA, carcinoembryonic antigen; CYFRA21-1, cytokeratin 19 fragment antigen; NSE, neuron-specific enolase.